Transposon Therapeutics
PrivateLast Round
Grant
Mar 4, 2026
Total Funding Raised
$54.12M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Transposon Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Debt round in July 2024.
Transposon Therapeutics is a biotechnology company developing a platform of novel nucleoside reverse transcriptase inhibitors for the treatment of neurodegenerative and aging-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Transposon Therapeutics Comparables
Compare Transposon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Asceneuron | 78% | |
| Vesper Bio ApS | 71% | |
| Coya Therapeutics, Inc. | 70% |
For institutional investors. Book with your work email.
Transposon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 4, 2026 | ||||
| Grant | Jul 9, 2025 | ||||
| Debt | Jul 15, 2024 | ||||
| VC Round | Jan 12, 2023 | ||||
| Series A | Dec 9, 2020 | ||||
Seed | May 6, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Transposon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Domain Associates | Seed, Series A, VC Round |
| Canaan Partners | Seed, Series A, VC Round |
| Catalys Pacific | Series A |
| ARPA-H | Grant |
| Lumira Ventures | Series A |
| Alzheimer's Drug Discovery Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
$22M grant round closed.
- Jul 9, 2025
$5M grant from Alzheimer's Drug Discovery Foundation.
For institutional investors. Book with your work email.
Transposon Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Transposon Therapeutics's valuation, stock price, and market status.
Is Transposon Therapeutics a public or private company?
Transposon Therapeutics is a private company.
What is the current stock price of Transposon Therapeutics?
Transposon Therapeutics is a private company, so its shares have no public market price. Caplight tracks Transposon Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Transposon Therapeutics worth (valuation)?
Valuation information for Transposon Therapeutics is not publicly available.
Can I buy Transposon Therapeutics stock?
Transposon Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Transposon Therapeutics's last funding round?
Transposon Therapeutics's most recent funding round was Grant on March 4, 2026.
Who are the main investors in Transposon Therapeutics?
Key investors in Transposon Therapeutics include ARPA-H, Alzheimer's Drug Discovery Foundation.
Will Transposon Therapeutics IPO soon?
No public IPO plans have been announced for Transposon Therapeutics.
How can I track Transposon Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Transposon Therapeutics's shares on secondary markets.